A Fusion Protein of Derp2 Allergen and Flagellin Suppresses Experimental Allergic Asthma
10.4168/aair.2019.11.2.254
- Author:
Wenzhi TAN
1
;
Jin Hai ZHENG
;
Tra My Nu DUONG
;
Young Il KOH
;
Shee Eun LEE
;
Joon Haeng RHEE
Author Information
1. Clinical Vaccine R&D Center and Department of Microbiology, Chonnam National University Medical School, Gwangju, Korea. jhrhee@chonnam.ac.kr
- Publication Type:Original Article
- Keywords:
Asthma;
Derp2;
FlaB flagellin;
fusion protein;
Toll-like receptor 5
- MeSH:
Allergens;
Animals;
Asthma;
Eosinophils;
Flagellin;
Immunoglobulin E;
Inflammation;
Lung;
Mice;
Mites;
Ovalbumin;
Pyroglyphidae;
Rhinitis, Allergic;
Therapeutic Uses;
Toll-Like Receptor 5;
Vibrio vulnificus
- From:Allergy, Asthma & Immunology Research
2019;11(2):254-266
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The house dust mite (HDM) is one of the most important sources of indoor allergens and a significant cause of allergic rhinitis and allergic asthma. Our previous studies demonstrated that Vibrio vulnificus flagellin B (FlaB) plus allergen as a co-treatment mixture improved lung function and inhibited eosinophilic airway inflammation through the Toll-like receptor 5 signaling pathway in an ovalbumin (OVA)- or HDM-induced mouse asthma model. In the present study, we fused the major mite allergen Derp2 to FlaB and compared the therapeutic effects of the Derp2-FlaB fusion protein with those of a mixture of Derp2 and FlaB in a Derp2-induced mouse asthma model. METHODS: BALB/c mice sensitized with Derp2 + HDM were treated with Derp2, a Derp2 plus FlaB (Derp2 + FlaB) mixture, or the Derp2-FlaB fusion protein 3 times at 1-week intervals. Seven days after the final treatment, the mice were challenged intranasally with Derp2, and airway responses and Derp2-specific immune responses were evaluated. RESULTS: The Derp2-FlaB fusion protein was significantly more efficacious in reducing airway hyperresponsiveness, lung eosinophil infiltration, and Derp2-specific IgE than the Derp2 + FlaB mixture. CONCLUSIONS: The Derp2-FlaB fusion protein showed a strong anti-asthma immunomodulatory capacity, leading to the prevention of airway inflammatory responses in a murine disease model through the inhibition of Th2 responses. These findings suggest that the Derp2-FlaB fusion protein would be a promising vaccine candidate for HDM-mediated allergic asthma therapy.
